VolitionRX

VNRX · NYSE American

$0.1732−$0.0001 (−0.06%)TodayMarket closed · Oct 21, 4:41 AM ET

Prev close $0.1733

VNRX analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy3
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $13.89 (+7922.2% upside)

Low: $2.02
Now: $0.1732
High: $25.20

Upgrades and downgrades

The latest rating actions, newest first

VNRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Maxim Group	Jun 18, 2026	Initiates	Buy	$4.00	25%
D. Boral Capital	Apr 20, 2026	Downgrade	Buy → Hold	—	29%
HC Wainwright & Co.	Apr 2, 2026	Maintains	Buy	$1.50 → $1.00	40%
D. Boral Capital	Mar 31, 2026	Maintains	Buy	$3.00	29%
D. Boral Capital	Mar 26, 2026	Maintains	Buy	$3.00	29%
D. Boral Capital	Mar 18, 2026	Maintains	Buy	$3.00	29%
D. Boral Capital	Jan 21, 2026	Maintains	Buy	$3.00	29%
D. Boral Capital	Jan 9, 2026	Maintains	Buy	$3.00	29%
D. Boral Capital	Dec 18, 2025	Maintains	Buy	$5.00 → $3.00	29%
D. Boral Capital	Dec 4, 2025	Maintains	Buy	$5.00	29%

The case for and against

Updated Sep 22, 2026

Bull case

VolitionRX is a promising company with a strong human diagnostics and monitoring focus, backed by revolutionary science and a dedicated team. However, recent reverse split actions may have negatively impacted stock value, shareholder base and liquidity, requiring time to repair and potentially indicating further shareholder concerns for the future. As an analyst it would be important to closely monitor future financial reports and announcements to fully assess the impact of the reverse split on the company's long-term growth potential.

Bear case

VolitionRX is facing several risks to achieving success, including potential barriers to regulatory or clinical approval, financial hurdles and potential market share losses. Although the company's recent study showed promise in detecting cancer, a concerning level of debt and the need for future capital raises could add significant pressure to the stock. Furthermore, competition in the liquid biopsy market and the company's struggle to establish commercial traction could impede its growth potential.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.